ATC code G04
| ATC code G: Genito-urinary system and sex hormones | 
|---|
  | 
| ATCvet only | 
  | 
| Other ATC codes | 
ATC code G04 Urologicals is a therapeutic subgroup of the Anatomical Therapeutic Chemical Classification System, a system of alphanumeric codes developed by the World Health Organization (WHO) for the classification of drugs and other medical products.[1][2][3] Subgroup G04 is part of the anatomical group G Genito-urinary system and sex hormones.[4]
Codes for veterinary use (ATCvet codes) can be created by placing the letter Q in front of the human ATC code: for example, QG04.[5] ATCvet codes without corresponding human ATC codes are cited with the leading Q in the following list.
National issues of the ATC classification may include additional codes not present in this list, which follows the WHO version.
G04B Urologicals
G04BA Acidifiers
- G04BA01 Ammonium chloride
 - G04BA03 Calcium chloride
 - QG04BA90 Methionine
 
G04BC Urinary concrement solvents
- Empty group
 
G04BD Drugs for urinary frequency and incontinence
- G04BD01 Emepronium
 - G04BD02 Flavoxate
 - G04BD03 Meladrazine
 - G04BD04 Oxybutynin
 - G04BD05 Terodiline
 - G04BD06 Propiverine
 - G04BD07 Tolterodine
 - G04BD08 Solifenacin
 - G04BD09 Trospium
 - G04BD10 Darifenacin
 - G04BD11 Fesoterodine
 - G04BD12 Mirabegron
 - G04BD13 Desfesoterodine
 - G04BD14 Imidafenacin
 - G04BD15 Vibegron
 
G04BE Drugs used in erectile dysfunction
- G04BE01 Alprostadil
 - G04BE02 Papaverine
 - G04BE03 Sildenafil
 - G04BE04 Yohimbin
 - G04BE05 Phentolamine
 - G04BE06 Moxisylyte
 - G04BE07 Apomorphine
 - G04BE08 Tadalafil
 - G04BE09 Vardenafil
 - G04BE10 Avanafil
 - G04BE11 Udenafil
 - G04BE30 Combinations
 - G04BE52 Papaverine, combinations
 
QG04BQ Urinary alkalizers
- QG04BQ01 Sodium bicarbonate
 
G04BX Other urologicals
- G04BX01 Magnesium hydroxide
 - G04BX03 Acetohydroxamic acid
 - G04BX06 Phenazopyridine
 - G04BX10 Succinimide
 - G04BX11 Collagen
 - G04BX12 Phenyl salicylate
 - G04BX13 Dimethyl sulfoxide
 - G04BX14 Dapoxetine
 - G04BX15 Pentosan polysulfate sodium
 - G04BX16 Tiopronin
 - G04BX17 Sodium salicylate and methenamine
 - QG04BX56 Phenazopyridine, combinations
 - QG04BX90 Ephedrine
 - QG04BX91 Phenylpropanolamine
 
G04C Drugs used in benign prostatic hypertrophy
G04CA Alpha-adrenoreceptor antagonists
- G04CA01 Alfuzosin
 - G04CA02 Tamsulosin
 - G04CA03 Terazosin
 - G04CA04 Silodosin
 - G04CA51 Alfuzosin and finasteride
 - G04CA52 Tamsulosin and dutasteride
 - G04CA53 Tamsulosin and solifenacin
 - G04CA54 Tamsulosin and tadalafil
 - G04CA55 Doxazosin and finasteride
 
G04CB Testosterone-5-alpha reductase inhibitors
- G04CB01 Finasteride
 - G04CB02 Dutasteride
 - G04CB51 Finasteride and tadalafil
 
G04CX Other drugs used in benign prostatic hypertrophy
- G04CX01 Prunus africanae cortex
 - G04CX02 Sabalis serrulatae fructus
 - G04CX03 Mepartricin
 - G04CX04 Fexapotide
 - QG04CX90 Osaterone
 
References
- ↑ "ATC (Anatomical Therapeutic Chemical Classification System) – Synopsis". National Institutes of Health. Retrieved 1 February 2020.
 - ↑ World Health Organization. "Anatomical Therapeutic Chemical (ATC) Classification". World Health Organization. Retrieved 3 January 2022.
 - ↑ "Structure and principles". WHO Collaborating Centre for Drug Statistics Methodology. 15 February 2018. Retrieved 3 January 2022.
 - ↑ "ATC/DDD Index 2022: code G04". WHO Collaborating Centre for Drug Statistics Methodology.
 - ↑ "ATCvet Index 2022: code QG04". WHO Collaborating Centre for Drug Statistics Methodology.
 
    This article is issued from Wmcloud. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.